Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036914 · ClinicalTrials.gov registry record · Phase 2
A Study of Ultra High Dose Diuretics to Treat Heart Failure
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06036914: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT06036914 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06036914, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.
Interventions
- DRUG Furosemide
- DRUG Bumetanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06036914
The ClinicalTrials.gov registry entry for NCT06036914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Furosemide is the first listed.
NCT06036914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06036914 about?
NCT06036914 is a clinical study titled "A Study of Ultra High Dose Diuretics to Treat Heart Failure". The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.
What is the current status of trial NCT06036914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-11-27. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT06036914?
The interventions under investigation include: Furosemide (DRUG), Bumetanide (DRUG).
Who is sponsoring clinical trial NCT06036914?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.